Abstracts tagged "Sjögren’s syndrome"

Abstract Number: 0313 • ACR Convergence 2021
Do Primary Sjögren’s Syndrome Patients with Normal Major Salivary Gland Ultrasound Have Less Active Disease?
Katja Perdan Pirkmajer¹, Matija TOMSIC¹ and Alojzija Hocevar², ¹University Medical Centre Ljubljana, Ljubljana, Slovenia, ²UKC Ljubjana, Ljubjana, Slovenia
Background/Purpose: Ultrasonographically depicted morphological changes of major salivary glands (SG) have been recently correlated with the disease activity in primary Sjögren’s (pSS)1. The aim of…
Abstract Number: 0986 • ACR Convergence 2021
Ianalumab (VAY736) Safety and Efficacy in Patients with Sjögren’s Syndrome: 52 Week Results from a Randomized, Placebo-controlled, Phase 2b Dose-ranging Trial
Thomas Dörner¹, Simon J Bowman², Robert Fox³, Xavier Mariette⁴, Athena Papas⁵, Thomas Grader-Beck⁶, Ben A Fisher², Filipe Barcelos⁷, Salvatore De Vita⁸, Hendrik Schulze-Koops⁹, Robert Moots¹⁰, Guido Junge¹¹, Janice Woznicki¹², Monika Sopala¹¹, Wen-Lin Luo¹² and Wolfgang Hueber¹¹, ¹Charite Universitätsmedizin Berlin and Deutsches Rheumaforschungszentrum (DRFZ), Berlin, Germany, ²Department of Rheumatology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom, ³Scripps Memorial Hospital and Research Institute, San Diego, CA, ⁴Université Paris- Saclay, Rheumatology, Paris, France, ⁵Division of Oral Medicine, Tufts School of Dental Medicine, Boston, MA, ⁶Johns Hopkins University, Baltimore, MD, ⁷Instituto Português de Reumatologia, Lisbon, Portugal, ⁸Division of Rheumatology, DAME, University Hospital of Udine, Udine, Italy, ⁹Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, University of Munich, Munich, Germany, ¹⁰Academic Rheumatology Department, Aintree University Hospital, Liverpool, United Kingdom, ¹¹Novartis Pharma AG, Basel, Switzerland, ¹²Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Sjögren’s syndrome (SS) is an autoimmune disease affecting excretory glands and characterized by B-cell hyperactivity. Ianalumab (VAY736) is a human monoclonal antibody to B-cell…
Abstract Number: 105 • 2019 ACR/ARP Annual Meeting
The DLEU2/miR-15a/16-1 Cluster Inhibit Foxp3+ Treg Cells in Salivary Glands of pSS via Targeting Foxp3
Xuan Wang¹, Zhenzhen Wu ¹, Jincheng Pu ¹, Run Feng ¹ and Jianping Tang ¹, ¹1. Department of Rheumatology and Immunology, Tongji Hospital, Tongji University School of Medicine, Shanghai, Shanghai, China (People's Republic)
Background/Purpose: Primary Sjögren’s Syndrome (pSS) is a systemic autoimmune disease characterized by lymphocytic infiltration of the salivary and lacrimal glands cells form a large part…
Abstract Number: 2878 • 2013 ACR/ARHP Annual Meeting
The Importance Of Germinal Center-Like Structures In Primary Sjögren’s Syndrome Salivary Glands Beyond Lymphoma Risk
Elke Theander¹, Thomas Mandl², Rolf Liedholm³, Roland Jonsson⁴, Malin V. Jonsson⁵ and Gunnar Warfvinge⁶, ¹Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ²Dept of Rheumatology, Skåne University Hospital Malmo, Lund University, Sweden, Malmö, Sweden, ³Department of oral and maxillofacial surgery, Skåne University Hospital Malmö, Lund University, Malmö, Sweden, ⁴Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway, ⁵Department of Clinical Dentistry - Section for Oral and Maxillofacial Radiology, University of Bergen, Bergen, Norway, ⁶Department of oral pathology, Skåne University Hospital Malmö, Lund University, Malmö, Sweden
Background/Purpose: The association between germinal center (GC)-like structures and lymphoma in primary Sjögren's syndrome (pSS) has been demonstrated recently (1). Here we present a comprehensive…
Abstract Number: 2186 • 2012 ACR/ARHP Annual Meeting
Ultrasonography of Major Salivary Glands in Primary Sjögren’s syndrome
Malin V. Jonsson¹, Daniel Hammenfors², Johan G. Brun² and Roland Jonsson³, ¹Department of Clinical Dentistry - Section for Oral and Maxillofacial Radiology, University of Bergen, Bergen, Norway, ²Department of Rheumatology, Haukeland University Hospital, Bergen, Norway, ³Broegelmann Research Laboratory, the Gade Institute, University of Bergen, Bergen, Norway
Background/Purpose: Minor salivary gland biopsy is part of the diagnostic process for primary Sjögren’s syndrome (pSS), but is not suitable for repeated follow-up. Ultrasound (US)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].